Enliven Therapeutics, Inc.
ELVN
$20.70
$0.381.87%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -26.99% | -25.53% | -19.67% | -11.49% | -19.31% |
| Total Depreciation and Amortization | 3.85% | -6.33% | 2.56% | 2.56% | 5.41% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 106.33% | 73.89% | 376.00% | 258.36% | 13.59% |
| Change in Net Operating Assets | 107.14% | 46.15% | -109.33% | 58.25% | -455.27% |
| Cash from Operations | 16.53% | -3.28% | -37.82% | 23.29% | -69.60% |
| Capital Expenditure | -6,850.00% | 0.00% | 100.00% | -37.50% | 97.73% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -444.96% | 108.10% | -98.12% | 141.79% | 77.77% |
| Cash from Investing | -445.34% | 107.98% | -98.12% | 141.71% | 77.78% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 11,991.81% | -99.74% | 44,313.33% | -99.31% | 1,180.85% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 11,991.81% | -99.74% | 44,313.33% | 362.82% | 164.04% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 133.91% | -145.83% | -10.64% | 107.23% | 68.57% |